Understanding Risk Factors for Progressive Chronic Kidney Disease in Malawi to Inform Interventions for Earlier Detection and Prevention (Impso Study)

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Worldwide, the number of people living with long-term health conditions, including chronic kidney disease (CKD), is increasing. CKD is usually asymptomatic in early stages but can progress to advanced disease, including kidney failure, causing significant morbidity and mortality. In low-income countries of sub-Saharan Africa, including Malawi, treatments for kidney failure are not yet widely available and are prohibitively expensive . It is therefore vital to: (a) Prevent development of CKD in the first place (b) Detect CKD earlier so that more cost-effective treatments can be given to slow progression. There is little evidence on factors that drive CKD progression in Malawi, or on interventions that may be cost-effective for improving detection and slowing disease progression in this setting. This PhD will address these knowledge gaps, through the following aims: 1\) Determine the mortality associated with CKD, and the risk factors driving its development and progression in Malawian adults 2) Investigate the impacts of different models for integrating screening and prevention strategies for CKD and its risk factors into health services for other long-term conditions in low- and middle-income countries 3) With patients, carers, healthcare workers and policy makers, evaluate the feasibility and acceptability of different potential models for integrating CKD screening and prevention strategies into health services for high-risk patient groups in Malawi

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Adult ≥ 18 years at time of participation in 2013-16 NCD survey

• Living in one of the demographic surveillance sites (Chilumba, Karonga or Lilongwe area 25)

• Creatinine +/- cystatin C result available from serum sample taken in 2013-16 NCD survey

• eGFRcreat ≥60ml/min/1.73m3 at baseline (using creatinine tested on serum sample from 2013-16 survey)

• Participated and provided blood (serum) sample in 2022-25 long-term conditions (LTC) survey i.e. individual-level longitudinal paired serum samples available, including consent already given for testing of stored samples in future studies

⁃ As for Objective 1, PLUS:

• eGFRcystC \<90ml/min/1.73m3 at baseline (using cystatin C tested on 2013-16 serum sample)

• Participated and provided serum sample in 2022-25 long-term conditions (LTC) survey i.e. individual-level longitudinal paired serum samples available

• Still alive and living in one of the demographic surveillance sites

• Able to provide consent or assent with consent from an appropriate nominated guardian

⁃ Exlusion criteria:

• Declines consent

• Unable to consent or assent

• Children (\<18 years)

• Non-resident in study areas

• Acute physical or mental illness

• Hospital inpatient

• Hospital admission \>24 hours in past 90 days and \<90 days until study end

• Currently pregnant

Locations
Other Locations
Malawi
Malawi Epidemiology and Intervention Research Unit
RECRUITING
Chilumba
Contact Information
Primary
Laurence Tembo
laurence.tembo@meiru.mw
+265 888 348 705
Time Frame
Start Date: 2024-02-14
Estimated Completion Date: 2025-12
Participants
Target number of participants: 1100
Treatments
MEIRU rural population cohort
Adults aged \>=18 living in MEIRU's rural health demographic surveillance area (Karonga district)~No interventions to be administered; observational study only, with collection of survey data, blood samples and urine samples.
MEIRU urban population cohort
Adults aged \>=18 living in MEIRU's urben demographic surveillance area (Lilongwe Area 25)~No interventions to be administered; observational study only, with collection of survey data, blood samples and urine samples.
Related Therapeutic Areas
Sponsors
Collaborators: Wellcome Trust, London School of Hygiene and Tropical Medicine, Malawi Epidemiology and Intervention Research Unit, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Glasgow
Leads: Liverpool School of Tropical Medicine

This content was sourced from clinicaltrials.gov